First Subcutaneous Injectable Approved to Treat Generalized Myasthenia Gravis
The subcutaneous formulation of argenx’s Vyvgart has been approved by the U.S. Food and Drug Administration to treat generalized myasthenia gravis.
FDA Approves Roche’s Columvi to Treat Diffuse Large B-Cell Lymphoma in Adults
The U.S. Food and Drug Administration has approved Roche’s Columvi, an antibody-based therapy chemically known as glofitamab.
Drug Granted Fast Track Approval to Treat Refractory Lupus Nephritis
The US Food and Drug Administration has granted fast track designation for Kyverna Therapeutics’ KYV-101 to treat refractory lupus nephritis.
First Once-Daily Oral Plaque Psoriasis Drug Approved by FDA
The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib), a once-daily oral pill by Bristol Myers Squibb, for adults who have plaque psoriasis (a chronic, systemic, immune-mediated disease) severe enough to make them candidates for systemic therapy and phototherapy.
FDA Approves Humira Biosimilar to Treat Autoimmune Disorders
The U.S. Food and Drug Administration has approved Samsung Bioepis; Halima (adalimumab-bwwd) for the treatment of several autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease.
IVIG Improves Live Birth Rate in Women with Immune Conditions and Recurrent Pregnancy Loss: Review and Meta-Analysis
Dutch investigators conducted a systematic review and meta-analysis of studies on the effectiveness of IVIG treatment of this specific population.
IVIG Plus Glucocorticoids Superior to IVIG Alone for MIS-C Associated with COVID-19: Review and Meta-Analysis
A new systematic review and meta-analysis conducted by U.S. and Nepalese collaborators supports the use of IVIG with glucocorticoids compared to IVIG alone.
New Drugs Approved by FDA to Treat Eczema
AbbVie’s Rinvoq and Pfizer’s Cibinqo have been approved by the U.S. Food and Drug Administration (FDA) to treat moderate-to-severe atopic dermatitis.
FDA Approves Novartis’ Cosentyx to Treat Arthritis in Children and Adolescents
Novartis has received U.S. Food and Drug Administration (FDA) approval for its Cosentyx (secukinumab) to treat children and adolescents with enthesitis-related arthritis and psoriatic arthritis.
Many Clinically Stable CIDP Patients Can Safely Stop IVIG Maintenance Treatment
While intravenous immune globulin (IVIG) therapy is efficacious for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), the lack of biomarkers for disease activity makes the need for ongoing treatment difficult to assess.